- First Traditional Chinese Medicine (TCM) specialist on the List
Guangzhou, China (ACN Newswire) -
The 2021 Fortune Global 500 was released on Aug 2. Guangzhou Pharmaceutical Holdings Ltd (GPHL), China's largest pharmaceutical enterprise and largest Traditional Chinese Medicine (TCM) producer, ranked 468th on the list, becoming the first company to enter the Global 500 with TCM as its major business.
The Guangdong provincial government, Guangzhou municipal government, the Sun Yat-sen University and Maoming municipal government all sent congratulatory letters to GPHL. As a Global 500 enterprise, GPHL has become a model for other TCM companies in Guangdong, and China, to follow.
As the largest pharmaceutical manufacturer in China, GPHL owns HKEX-listed Guangzhou Baiyunshan Pharmaceutical Holdings Company Ltd (0867.HK) and more than 30 subsidiaries. Its four core businesses are Grand Southern TCM, Grand Health, Grand Commerce and Grand Medical Treatment.
Twelve of GPHL's TCM subsidiaries are Chinese time-honored brands, 10 of which enjoy a history of more than 100 years. Not surprisingly, GPHL ranked 19th in the 2021 Brand Finance Global 500 listing of Most Valuable Pharmaceutical Brands.
Li Chuyuan, GPHL chairman, said "Entering the Global Fortune 500 List is an important milestone on GPHL's path to becoming a first-class global enterprise. It should be attributed to Guangdong and Guangzhou's efforts to develop the TCM industry. GPHL will continue to provide solutions that enhance health and reduce medical costs."
Becoming the first TCM-based enterprise in the Fortune Global 500, GPHL is hastening its pace to become truly international
GPHL dates to the Ming Dynasty, when the Chenliji brand was founded in 1600. The 421-year-old Chenliji Pharmaceutical Factory has been certified by Guinness as the 'World's Oldest Operating Pharmaceutical Factory', and the 193-year-old Guangzhou Wanglaoji Pharmaceutical Co Ltd is regarded as the originator of herbal tea.
Yet, GPHL proposed a "Trendy TCM" and cooperation with other industries to develop TCM. To this end, GPHL and PepsiCo's Quaker developed healthy and trendy instant oatmeal products which incorporate Chinese traditional style and culture, and GPHL developed a Ciningji product line based on Guizhou's roxburgh rose.
Now, GPHL is researching and developing new beverage products made with lychee, aiming to promote the famous Guangdong fruit and support rural revitalization businesses in China.
Growing through scientific and technological innovation, Powering the development engine of the health and medicine industry
GPHL understands the importance of scientific and technological innovation and strives to build a talent plateau. Presently, GPHL has 3 Nobel Prize winners, 19 domestic academicians and masters of traditional Chinese medicine, 7 foreign expert consultants, nearly 100 doctors and post-docs, and has built 10 national research institutes.
While GPHL has been the top pharmaceutical and TMC enterprise in China for ten consecutive years, this isn't all. GPHL's chemical and biological drug businesses are also the leaders in China, and under GPHL, Guangzhou Pharmaceutical Co., Ltd. has become the largest commercial medical distributor in China.
Committed to building a world-class enterprise, Providing a broad programme to improve the world health
In order to internationalize, GPHL has been enhancing its research partnerships and participating in forums such as the Fortune Global Forum and Boao Forum for Asia to partner with Fortune Global 500 companies. It signed an MoU with Merck in March this year to push forward cooperation on an R&D, business model and market expansion.
To further integrate domestic and foreign markets, GPHL set up its international headquarters, Guangzhou Pharmaceutical Group (Macau) International Development Co., in China's Macao SAR. It aims to promote collaboration within the Guangdong-Hong Kong-Macao Greater Bay Area, and speed up GPHL's course of internationalization.
What's more, GPHL has established joint ventures with Walgreens Boots Alliance, Baxter and other enterprises in addition to its strategic partnerships with Pepsi, Merck and Takeda. In its strategic plans, GPHL will concentrate its efforts on building a world-class biomedical and healthcare enterprise, improving the world's health and reducing its medical expenditures over the next years.
For more information, please contact Liusheng Yu at Guangzhou Pharmaceutical Holdings Limited, http://www.gpc.com.cn, Tel +86 17600659000.
